Published in Cancer Weekly, September 5th, 2006
According to a report from New Zealand, "The purpose of this study was to investigate the immunogenicity of liposomes containing mannosylated lipid core peptide (manLCP) constructs, both in vitro and in vivo, with or without the addition of the immune stimulating adjuvant Quil A."
"Mouse bone marrow dendritic cells (BMDC) were cultured with liposome formulations for 48 hours, and the resulting level of BMDC activation was determined by flow cytometry," said Karen White and colleagues at the University of Otago...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.